Clinical Trial Update: Evaluate Safety and Pharmacokinetics of INF904 in Subjects With Moderate to Severe Chronic Spontaneous Urticaria or Hidradenitis Suppurativa [Phase 2]

View source ↗

Summary

Phase 2 study evaluating safety and pharmacokinetics of INF904 in adults with chronic spontaneous urticaria or hidradenitis suppurativa was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hidradenitis Suppurativa
• Spontaneous Urticaria

Drugs mentioned

• INF904 (INF904)

Snippet

Sponsor: InflaRx GmbH | Conditions: Chronic Urticaria, Idiopathic, Hidradenitis | Phase 2 | Status: TERMINATED